NET CLINICAL TRIALS IN CANADA
For an up-to-date listing of all active recruiting NET Clinical Trials please visit: Neuroendocrine Tumour Open Trials – Canada
The following information on active Neuroendocrine clinical trials in Canada was taken from the clinicaltrials.gov website.
Click on each trial to go to more information including protocol, objectives, entry criteria, investigators and locations in Canada.
| Status | Study Title | Intervention | Locations |
|---|---|---|---|
| Recruiting | 68Ga-DOTA-TATE PET/CT Imaging in NETs | Diagnostic Test: 68Ga-DOTA-TATE | CHUS Sherbrooke, Quebec, Canada |
| Recruiting | A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours | Drug: [177]Lu-DOTA-TATE | Cross Cancer Institute Edmonton, Alberta, Canada |
| Recruiting | 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors | Diagnostic Test: 68Ga -DOTATATE PET scans | Princess Margaret Cancer Centre Toronto, Ontario, Canada |
| Recruiting | DOTATOC PET/CT for Imaging NET Patients | Diagnostic Test: 68Ga-DOTATOC PET/CT
Diagnostic Test: 18F-FDG PET/CT |
BC Cancer Vancouver, British Columbia, Canada |
| Recruiting | Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors | Diagnostic Test: 18F-DOPA with furosemide | University of Alberta Hospital Edmonton, Alberta, Canada |
| Recruiting | Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors | Drug: F18-FDG | Princess Margaret Cancer Centre Toronto, Ontario, Canada |
| Recruiting | Personalized PRRT of Neuroendocrine Tumors | Drug: 177Lu-Octreotate | CHU de Québec – Université Laval Quebec City, Quebec, Canada |
| Recruiting | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | Drug: CAM2029
Drug: Octreotide LAR Drug: Lanreotide ATG |
|
| Recruiting | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use | Drug: [68]Ga-HA-DOTATATE | Cross Cancer Institute Edmonton, Alberta, Canada |
| Recruiting | 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors | Drug: 68Ga-HA-DOTATATE | University of Alberta Edmonton, Alberta, Canada |
| Recruiting | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging | Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 68Ga-DOTATOC PET/CT |
BC Cancer Vancouver, British Columbia, Canada |
| Recruiting | 18F-DOPA II – PET Imaging Optimization | Drug: 18F-DOPA
Drug: Furosemide Injection |
WC Mackenzie Health Science Centre / University of Alberta Hospital Edmonton, Alberta, Canada |
| Not yet recruiting | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | Drug: 177Lu-DOTATOC | BC Cancer Vancouver, British Columbia, Canada |
| Recruiting | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | Drug: Lutetium [177Lu] oxodotreotide/dotatate | CHU de Québec – Université Laval Québec, Canada |
| Recruiting | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | Drug: [Ga-68]-PNT6555
Drug: [Lu-177]-PNT6555 |
University Health Network – Princess Margaret Cancer Centre Toronto, Ontario, CanadaCHUM – Centre hospitalier de l’Université de Montréal Montréal, Quebec, CanadaJewish General Hospital Montréal, Quebec, Canada |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
